NY-ESO-1 Gains Momentum as a Therapeutic Target

Morgan E. Meissner, PhD
Published: Friday, Aug 02, 2019
As the immunotherapy research field grows, NY-ESO-1 is emerging as a high-priority target for cancer vaccine development and adoptive T-cell therapies. Promising results have been obtained from early studies, prompting the rapid expansion of the field. Consequently, NY-ESO-1 was the target of 37% of all active clinical trials utilizing T-cell receptor (TCR)-based adoptive T-cell therapy, according to an analysis of studies updated as of June 2018.1

The restricted expression profile of NY-ESO-1 in healthy adult tissues makes this protein an ideal anticancer target because there is a low risk of off-target toxicities caused by treatment.

Figure. Immunotherapy Opportunities for Targeting NY-ESO-12

FIGURE. IMMUNOTHERAPY OPPORTUNITIES FOR TARGETING NY-ESO-12 The protein also has been shown to spontaneously elicit both humoral and cellular immune responses in patients with cancer, making NY-ESO-1 a prime target for immunotherapy-based treatments. Several studies have found that NY-ESO-1 is able to stimulate IgG responses in many cancer types.2,3 The findings from an analysis of 1969 tumors of various cancer types confirmed stimulation of an anti–NY-ESO-1 humoral response in the serum of patients with esophageal, lung, hepatocellular, prostate, gastric, colorectal, or breast cancers.3
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x